Aarti Drugs has received Establishment Inspection Report (EIR) from USFDA concluding the inspection as closed for its API manufacturing facility located at Plot No-E-22, MIDC, Tarapur, Maharashtra.
UFDA has determined that the inspection classification of this facility is “voluntary action indicated” (VAI). Based on this inspection, this facility is considered to be in a minimally acceptable state of compliance with
regard to current good manufacturing practice (CGMP).